Peter N. Kellogg

Chief Financial Officer, Biogen.

Companies

Alnylam PharmaceuticalsBoard member Mar 9, 2023 to now¹
Yield10 BioscienceBoard member Apr 10, 2007 to May 23, 2019²
Merck & Co.Chief financial officer Nov 5, 2009 to Feb 26, 2014³
Merck & Co.Exec. V.P. & C.F.O Nov 5, 2009 to Nov 5, 2009⁴
MERCK SHARP & DOHME LLCExec. V.P. & C.F.O. Aug 17, 2007 to Nov 4, 2009⁵
BiogenChief financial officer Feb 8, 2006 to Mar 22, 2007⁶

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

Alnylam Pharmaceuticals ALNY1,446 shares⁷$340.6K at $235.58May 20, 2026

As of each latest filing. The line shows shares held over time.

Recent filings

May 20, 2026Granted 671 shares of Alnylam Pharmaceuticals⁷
May 8, 2025Granted 775 shares of Alnylam Pharmaceuticals⁸

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARAlnylam Pharmaceuticals, Board member
2
SEC EDGARYield10 Bioscience, Board member
3
SEC EDGARMerck & Co., Chief financial officer
4
SEC EDGARMerck & Co., Exec. V.P. & C.F.O
5
SEC EDGARMERCK SHARP & DOHME LLC, Exec. V.P. & C.F.O.
6
SEC EDGARBiogen, Chief financial officer
7
SEC EDGARAlnylam Pharmaceuticals shares after the filing of May 20, 2026
8
SEC EDGARForm 4 filed May 12, 2025